A Phase 1 Dose-Escalation Study of the Cardiac Myosin Inhibitor Aficamten in Healthy Participants.

JACC Basic Transl Sci · 2022 · PMC9436819 · PMID 36061336

Europe PMC DOI

hedged sentence

0.2100

closest p · 4.2× alpha

0.2100

boldest claim

The sentences

did not reach statistical significanceP = 0.21not close (p > 0.1)

The placebo-corrected reduction of 3.2% (least-squares mean difference) did not reach statistical significance ( P = 0.21), likely because of the lack of statistical power in this small group comparison.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.